Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Checkpoint Therapeutics Inc

Healthcare US CKPT

NoneUSD
0.00(0%)

Last update at 2025-06-30T13:04:54.365253Z

Day Range

--
LowHigh

52 Week Range

1.303.62
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap68.54M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.07M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM -48.18500M
  • Diluted EPS TTM-2.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -51.84700M -62.62400M -56.67000M -23.08100M -24.71400M
Minority interest - - - - -
Net income -51.84700M -66.91500M -56.61700M -22.96100M -24.57800M
Selling general administrative 8.69M 8.70M 8.54M 7.92M 7.23M
Selling and marketing expenses 0.30M 0.40M - - -
Gross profit -43.46300M -49.63300M 0.27M 1.07M 1.71M
Reconciled depreciation - - - - -
Ebit - -58.33300M -56.72300M -23.20100M -24.85000M
Ebitda -52.14800M -53.88200M -56.67000M -23.20100M -24.85000M
Depreciation and amortization - 4.45M 0.05M - -
Non operating income net other - - 0.05M 0.12M 0.14M
Operating income -52.14800M -58.33300M -56.72300M -23.20100M -24.85000M
Other operating expenses 52.25M 58.52M 56.99M 24.27M 26.56M
Interest expense - 4.29M 0.05M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.15M 0.16M 0.05M 0.12M 0.14M
Net interest income 0.15M 0.16M 0.05M 0.12M 0.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 4.29M -0.05300M -0.12000M -0.13600M
Total revenue 0.10M 0.19M 0.27M 1.07M 1.71M
Total operating expenses 52.25M 58.52M 56.99M 24.27M 26.56M
Cost of revenue 43.57M 49.83M 48.45M 16.35M 19.32M
Total other income expense net 0.30M -4.29100M 0.05M 0.12M 0.14M
Discontinued operations - - - - -
Net income from continuing ops -53.74100M -62.62400M -56.67000M -23.08100M -24.71400M
Net income applicable to common shares - - -56.67000M -23.08100M -24.71400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5.38M 13.29M 55.73M 42.60M 26.97M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.45M 1.15M 0.98M 1.80M 0.86M
Total liab 18.43M 32.77M 25.98M 7.22M 8.12M
Total stockholder equity -13.04700M -19.48300M 29.75M 35.38M 18.85M
Deferred long term liab - - - - -
Other current liab 9.04M 11.17M 8.78M 2.93M 4.18M
Common stock 3.42M 0.00100M 0.00900M 0.00700M 0.00600M
Capital stock 0.00300M 0.00100M 0.00900M 0.00700M 0.00600M
Retained earnings -314.33300M -262.48600M -199.86200M -143.19200M -120.11100M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 4.93M 12.07M 54.73M 40.77M 26.08M
Cash and equivalents - - - - -
Total current liabilities 18.43M 32.77M 25.98M 7.22M 8.12M
Current deferred revenue - - - - -
Net debt -4.92800M -12.06800M -54.73500M -40.77200M -26.07700M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 294.44M 243.00M 229.60M 178.56M 138.95M
Property plant equipment - - - - -
Total current assets 5.38M 13.29M 55.73M 42.60M 26.97M
Long term investments - - - - -
Net tangible assets - - 29.75M 35.38M 18.85M
Short term investments - - - - -
Net receivables - 0.07M 0.02M 0.02M 0.03M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 9.38M 21.60M 17.20M 7.22M 3.94M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.42M - - - -
Additional paid in capital - - - - -
Common stock total equity - - 0.00900M 0.00700M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - - -199.86200M -143.19200M -120.11100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - - - - -
Change to liabilities - - 18.77M -0.83300M -5.04300M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 40.45M 14.89M 40.27M 31.25M 25.45M
Change to operating activities - - 0.83M -0.94100M 0.51M
Net income -51.84700M -62.62400M -56.67000M -23.08100M -24.71400M
Change in cash -7.14000M -42.66700M 13.96M 14.70M 4.08M
Begin period cash flow 12.07M 54.73M 40.77M 26.08M 22.00M
End period cash flow 4.93M 12.07M 54.73M 40.77M 26.08M
Total cash from operating activities -47.59000M -57.55400M -26.30600M -16.55100M -21.37300M
Issuance of capital stock 41.30M 17.62M 41.28M 33.27M 27.57M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - 0.06M -0.00300M -0.00600M -1.50600M
Change to account receivables 0.07M -0.05600M 0.00300M 0.00600M 1.51M
Sale purchase of stock 1.69M -0.00600M 0.00000M 0.01M 27.57M
Other cashflows from financing activities 40.45M -2.72700M -1.01000M -2.02100M -2.11600M
Change to netincome - - 10.77M 3.68M 3.86M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - 0.00300M 0.00600M 1.51M
Cash flows other operating - - 7.43M 3.68M 3.02M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 13.96M 14.70M 4.08M
Change in working capital -2.79400M -4.60800M 19.60M -1.76800M -3.02800M
Stock based compensation 2.90M 2.92M 3.14M 2.78M 3.12M
Other non cash items 4.15M 6.75M 7.63M 5.52M 3.25M
Free cash flow -47.59000M -57.55400M -26.30600M -16.55100M -21.37300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CKPT
Checkpoint Therapeutics Inc		 - -% - - - 616.71 8.56 568.87 -1.1236
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics Inc

95 Sawyer Road, Waltham, MA, United States, 02453

Key Executives

Name Title Year Born
Mr. James F. Oliviero III, C.F.A., CFA Pres, CEO & Director 1976
Mr. William Garrett Gray CFO, Corp. Sec. & Treasurer 1987
Mr. James F. Oliviero III, C.F.A. President, CEO & Director 1976
Mr. William Garrett Gray CFO, Corporate Secretary & Treasurer 1987

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.